Gefitinib-associated lichen planus pigmentosus-like eruption.

Dermatol Online J

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Skin and Allergy Research Unit, Chulalongkorn University, Bangkok.

Published: May 2021

The epidermal growth factor receptor (EGFR) signaling pathway is one of the oncogenic pathways in non-small cell lung cancer. Gefitinib is classified as a first-generation EGFR-tyrosine kinase inhibitor (TKI). A variety of cutaneous adverse effects related to the drug has been reported. Cutaneous hyperpigmentation is a rare side effect of EGFR inhibitor (EGFRi). Herein, we report a 62-year-old woman with non-small cell lung carcinoma who presented with symmetrical, slate-gray-to-brownish-black macular pigmentation on sun-exposed and non-sun-exposed areas after eight months of gefitinib administration. The clinical features were consistent with lichen planus pigmentosus. This case highlights the unusual hyperpigmented condition occurring in patients taking EGFR-TKIs.

Download full-text PDF

Source
http://dx.doi.org/10.5070/D327553616DOI Listing

Publication Analysis

Top Keywords

lichen planus
8
non-small cell
8
cell lung
8
gefitinib-associated lichen
4
planus pigmentosus-like
4
pigmentosus-like eruption
4
eruption epidermal
4
epidermal growth
4
growth factor
4
factor receptor
4

Similar Publications

This research is purposed to synthesize the existing evidence on implant survival rates in patients with oral potentially malignant disorders (OPMD) and assess potential risk factors associated with peri-implant disease. A comprehensive search was performed across PubMed MEDLINE, Cochrane Library, and Web of Science. This review was conducted according to the PRISMA guidelines, including studies published between 2012 and 2023.

View Article and Find Full Text PDF

Introduction: Acquired inflammatory Blaschko-linear dermatoses have not been studied extensively. Descriptive studies on segmental vitiligo have yielded insights helpful in counseling patients. Similar insights are expected from studies on other acquired inflammatory Blaschko-linear diseases.

View Article and Find Full Text PDF

Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.

Indian Dermatol Online J

December 2024

Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.

Background: Inflammatory dermatological conditions, including psoriasis, lichen planus, eczema, and alopecia areata, are frequently accompanied by nail findings and can have a significant impact on quality of life. Biologic and small-molecule medications have been approved over the past several decades in treating patients with these inflammatory nail disorders. They may be used in conjunction with longstanding mainstays of treatment (topical and intralesional corticosteroids, topical vitamin D3 analogs).

View Article and Find Full Text PDF

Multinucleate cell angiohistiocytoma (MCAH) is a rare benign cutaneous entity. It classically presents as slowly progressive erythematous to violaceous papules on the distal extremities of middle-aged or elderly women. The entity may clinically resemble granuloma annulare, lichen planus, and several cutaneous vascular proliferations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!